Dey L.P. to Market EMSAM Skin Patch for Treatment of Major Depressive Disorder Dey L.P., a subsidiary of Mylan Inc. , announced that it has begun to market and distribute EMSAM in the U.S. EMSAM, a selegiline transdermal system, is a monoamine oxidase inhibitor, which was approved by the U.S. Food and Drug Administration in 2006 for the treatment of major depressive disorder. [more...]
